
Opinion|Videos|May 8, 2024
Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials
Sarah Rockwell, PharmD, BCOP, provides an overview of the safety and efficacy data of bispecific antibodies investigated in the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 trials, providing critical insights into the results of each study.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves mFlusiva, the First mRNA-Based Influenza Vaccine
2
FDA Approves Oveporexton for Narcolepsy Type 1
3
KRAS-Targeted Peptide Vaccine Generates Durable Responses, Shows Promise in High-Risk Pancreatic Cancer
4
Erica Schwartz Confirmed as CDC Director Amid Public Health Crises
5







































































































